MCM
AVIR icon

MAI Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History

MAI Capital Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$711 Buy
132
+37
+39% +$170 ﹤0.01% 4297
2025
Q4 		$340 Hold
95
– – ﹤0.01% 3935
2025
Q3 		$276 Hold
95
– – ﹤0.01% 3683
2025
Q2 		$342 Hold
95
– – ﹤0.01% 3814
2025
Q1 		$285 Hold
95
– – ﹤0.01% 3288
2024
Q4 		$319 Buy
+95
New +$316 ﹤0.01% 3337

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MAI Capital Management's AVIR Position: Q1 2026 in Review

MAI Capital Management increased its Atea Pharmaceuticals (AVIR) stake by 39% in Q1 2026, buying an estimated $170 and bringing the position to 132 shares worth $711. The position accounts for ﹤0.01% of the portfolio, ranked #4297.

MAI Capital Management first reported a position in AVIR in Q4 2024 and has held it in 6 quarters since. 127 funds tracked by Wall St. Rank hold AVIR as of Q1 2026.

  • MAI Capital Management held 132 shares of Atea Pharmaceuticals worth $711 as of Q1 2026.
  • MAI Capital Management bought 37 Atea Pharmaceuticals shares in Q1 2026, an estimated $170.
  • Atea Pharmaceuticals made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4297 holding.
  • MAI Capital Management first reported a position in Atea Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.